Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease

By afschroeder • March 25, 2026

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, Sauk JS. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2026 Mar 24. doi: 10.1007/s10620-026-09797-7. Epub ahead of print. PMID: 41874779.

Tags: Adverse events, Anti-tumor necrosis factor, Digestive Diseases, General Internal Medicine, inflammatory bowel disease, long-term, Publications, Resident, safety

JPEN Journal Club 99. ICEMAN analyses

Koretz RL. JPEN Journal Club 99. ICEMAN analyses. JPEN J Parenter Enteral Nutr. 2026 Mar 17. doi: 10.1002/jpen.70072. Epub ahead of print. PMID: 41846318.

Perceived Utility of Cognitive Behavioral Therapy in People With Bowel Disorders of Gut-Brain Interaction

Veraza DI, Waseem MR, Venezia J, Montero AM, Jones S, Kadariya J, Gupta A, Xu H, Shin A. Perceived Utility of Cognitive Behavioral Therapy in[...]

Evaluating the Impact of Different Biliary Stents for Bile Leak Following Fenestrated Cholecystectomy: A Retrospective Multicenter Study

Turner R, Mendez D, Karna R, Liu PH, Issa D, Bilal M, Shah S, Ellis D, Tielleman T. Evaluating the Impact of Different Biliary Stents[...]